itSpray Announces BOOSTit with New Ingredients Elderberry and Monk Fruit Coming Soon

February 8, 2021

itSpray founder Kimberly Stiele said, “At itSpray we strive to give you the best solutions for your total health needs. We continue to improve our products to help you pursue a healthier lifestyle with ease, including immune support, sustained energy, and sleep solutions. Which is why Drug Store News has named BOOSTit a Who’s Who of Immunity products.”

BOOSTit is a solution for immune support and contains many essential vitamins. These include vitamins A, C, D, B-12 and B2. These vitamins along with other natural ingredients, encourage white blood cell production and strengthen the immune system.

Elderberry (scientific name is sambucus), the first new ingredient in BOOSTit, comes from the European elder tree and is a type of flowering plant. According to Medical News Today, the dark purple berries and flowers contain many antioxidants that support the immune, including vitamin C, vitamin A, and iron. In addition to immune support, iron helps with energy, focus, digestion, and body temperature maintenance.

Monk fruit sweetener has replaced sucralose, the sweetener previously used in BOOSTit. Monk fruit, as defined by monkfruit.org, is a small, sub-tropical melon that has been cultivated for centuries. It is a super-fruit that acts as a natural sweetener. Monk fruit is able to provide a sweet flavor without the calories, and is rich in antioxidants. Since 2009, more than 800 products have used monk fruit sweetener. A few of the health benefits of monk fruit include weight loss, protection against diabetes, and immune support, according to Conserve Energy Future.

We expect a lot of interest in BOOSTit as our customers have been awaiting the arrival of the new formula. Your body works hard for you and will thank you for treating it with care it deserves.

SourceitSpray

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”